https://www.nasdaq.com/press-release/alector-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-2022-01-03
https://www.nasdaq.com/press-release/alector-announces-appointment-of-sara-kenkare-mitra-ph.d.-as-president-and-head-of
https://www.nasdaq.com/press-release/alector-presents-encouraging-new-al001-data-from-the-symptomatic-ftd-grn-cohort-of
https://www.nasdaq.com/press-release/alector-presents-preclinical-data-from-al009-multi-siglec-inhibitor-program-at-the
https://www.nasdaq.com/press-release/alector-presents-new-data-from-multiple-pipeline-programs-at-2021-ctad-conference
https://www.nasdaq.com/press-release/alector-to-present-at-the-stifel-2021-virtual-healthcare-conference-2021-11-08
https://www.nasdaq.com/press-release/alector-reports-third-quarter-2021-financial-results-2021-11-04
https://www.nasdaq.com/press-release/alector-to-present-new-data-from-multiple-pipeline-programs-at-2021-ctad-conference
https://www.nasdaq.com/press-release/alector-announces-appointment-of-elizabeth-a.-garofalo-m.d.-to-its-board-of-directors
https://www.nasdaq.com/press-release/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al001-in
https://www.nasdaq.com/press-release/alector-provides-executive-leadership-update-2021-09-07
https://www.nasdaq.com/press-release/alector-to-present-at-upcoming-virtual-healthcare-conferences-2021-09-02
https://www.nasdaq.com/press-release/alector-reports-second-quarter-2021-financial-results-2021-08-03
https://www.nasdaq.com/press-release/alector-presents-12-month-results-from-the-infront-2-phase-2-open-label-clinical
https://www.nasdaq.com/press-release/alector-to-present-new-data-from-frontotemporal-dementia-and-alzheimers-disease
https://www.nasdaq.com/press-release/alector-and-gsk-announce-global-collaboration-in-immuno-neurology-for-two-clinical
https://www.nasdaq.com/press-release/alector-to-present-at-upcoming-virtual-healthcare-conferences-2021-06-03
https://www.nasdaq.com/press-release/centogene-initiates-efront-study-to-identify-patients-with-genetic-forms-of
https://www.nasdaq.com/press-release/alector-to-host-virtual-key-opinion-leader-event-on-frontotemporal-dementia-on-june
https://www.nasdaq.com/press-release/alector-to-present-at-the-bofa-securities-2021-virtual-health-care-conference-2021-05
https://www.nasdaq.com/press-release/alector-reports-2021-first-quarter-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/alector-to-present-at-stifels-3rd-annual-cns-day-2021-03-25
https://www.nasdaq.com/press-release/alector-to-present-at-the-barclays-global-healthcare-conference-2021-03-04
https://www.nasdaq.com/press-release/alector-reports-2020-fourth-quarter-and-full-year-financial-results-and-provides
https://www.nasdaq.com/press-release/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in
https://www.nasdaq.com/press-release/alector-announces-departure-of-chief-business-officer-2021-01-20
https://www.nasdaq.com/press-release/alector-provides-2021-corporate-portfolio-update-2021-01-07
https://www.nasdaq.com/press-release/alector-to-present-at-the-stifel-2020-virtual-healthcare-conference-2020-11-11
https://www.nasdaq.com/press-release/alector-reports-third-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/alector-provides-update-on-arbitration-proceedings-with-dr.-asa-abeliovich-2020-11-02
https://www.nasdaq.com/press-release/alector-to-highlight-early-stage-cancer-programs-at-upcoming-scientific-forums-2020
https://www.nasdaq.com/press-release/alector-to-participate-at-virtual-investor-conferences-in-september-2020-09-03
https://www.nasdaq.com/press-release/alector-reports-second-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/alector-to-present-at-the-btig-virtual-biotechnology-conference-2020-2020-08-04
https://www.nasdaq.com/press-release/alector-announces-promising-preliminary-data-from-al001-phase-1b-and-phase-2-open
https://www.nasdaq.com/press-release/alector-doses-first-patient-in-pivotal-phase-3-infront-3-trial-evaluating-al001-in
https://www.nasdaq.com/press-release/alector-to-present-data-from-the-al001-phase-2-open-label-study-in-frontotemporal
https://www.nasdaq.com/press-release/alector-announces-publication-of-preclinical-and-phase-1-data-validating-potential-of
https://www.nasdaq.com/press-release/alector-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-2020
https://www.nasdaq.com/press-release/alector-reports-2020-first-quarter-financial-results-and-business-highlights-2020-05
https://www.nasdaq.com/press-release/alector-to-present-at-the-bank-of-america-securities-virtual-health-care-conference
https://www.nasdaq.com/press-release/alector-enters-into-a-licensing-agreement-with-innovent-biologics-to-develop-and
https://www.nasdaq.com/press-release/alector-reports-2019-fourth-quarter-and-full-year-financial-results-and-business
https://www.nasdaq.com/press-release/alector-announces-the-appointment-of-paula-hammond-ph.d.-to-the-board-of-directors
https://www.nasdaq.com/press-release/alector-to-present-at-the-cowen-40th-annual-health-care-conference-2020-02-24
https://www.nasdaq.com/press-release/alector-announces-fda-fast-track-designation-granted-to-al101-for-the-treatment-of
https://www.nasdaq.com/press-release/alector-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of
https://www.nasdaq.com/press-release/alector-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares
https://www.nasdaq.com/press-release/alector-announces-upsizing-and-pricing-of-public-offering-2020-01-29
https://www.nasdaq.com/press-release/alector-announces-initiation-of-phase-1b-study-of-al003-in-alzheimers-disease
https://www.nasdaq.com/press-release/alector-announces-proposed-public-offering-of-common-stock-2020-01-27
https://www.nasdaq.com/press-release/alector-to-present-at-the-j.p.-morgan-38th-annual-healthcare-conference-2020-01-08
https://www.nasdaq.com/press-release/alector-initiates-first-in-human-dosing-in-phase-1-study-of-al101-for-the-treatment
https://www.nasdaq.com/press-release/alector-added-to-the-nasdaq-biotechnology-index-2019-12-20
https://www.nasdaq.com/press-release/alector-appoints-dr.-richard-scheller-lasker-prize-awarded-scientist-and-dr.-thomas
https://www.nasdaq.com/press-release/alector-showcases-progress-in-immuno-neurology-clinical-programs-and-research
https://www.nasdaq.com/press-release/alector-announces-appointment-of-shehnaaz-suliman-m.d.-mba-m.phil.-as-president-and
https://www.nasdaq.com/press-release/alector-announces-phase-1-data-on-al002-at-the-12th-clinical-trials-on-alzheimers
https://www.nasdaq.com/press-release/alector-announces-fda-fast-track-designation-granted-to-al001-for-the-treatment-of
https://www.nasdaq.com/press-release/alector-to-host-rd-day-on-december-13-2019-2019-12-04
